A therapeutic innovation for dystonic motor disorders related to Parkinson's disease

A.F. GENESE Med: Redefining mobility in Parkinson's disease

The A.F. GENESE Med program represents the culmination of our commitment to research. This therapeutic innovation project specifically targets one of the most disabling symptoms for patients with Parkinson's disease: dystonic motor disorders.

The challenge: beyond tremor

While Parkinson's disease is often associated with resting tremor, dystonic disorders—characterized by involuntary, prolonged, and often painful muscle contractions—profoundly impair patients' quality of life and autonomy. These symptoms sometimes resist conventional treatments, creating a major unmet medical need.

Our therapeutic innovation

A.F. GENESE MED is based on a disruptive approach to neurological modulation

Regulation

Regulate the neural signals responsible for abnormal muscle contractions
01

Reduction

Reduce the impact of dyskinesias (involuntary movements) induced by long-term dopaminergic treatments
02

Restoration

Restore movement fluidity by acting on synaptic plasticity
03

A.F. GENESE technology bridges the most rigorous fundamental research and the concrete daily needs of patients and users.

Toward a Pivotal Clinical Phase

The A.F. GENESE Med project is currently entering a pivotal phase of its development.
In collaboration with the Brain and Mind biocluster, we are consolidating evidence of efficacy to provide a concrete and safe therapeutic response to the thousands of people affected by these motor disorders.
2025

E-Tonus

E-Tonus is an innovative wellness device, developed and manufactured in France by A.F. GENESE. Based on its exclusive and patented technology, the device has already gained more than 300 daily users since its launch in July 2025. This real-world success constitutes major proof of concept, enabling A.F. GENESE to establish the clinical and technological foundations for its future medical device.

2025
E-Tonus
2026

Pilot Study

Evaluation of the efficacy of E-Tonus in dystonia associated with Parkinson's disease: a multicenter, randomized, double-blind, placebo-controlled trial.

2026
Pilot Study
2027

A.F. GENESE Med

Design and prototyping in compliance with ISO 13485 standard requirements.

2027
A.F. GENESE Med
2028

Pivotal Study

Evaluation of the efficacy and safety of A.F. GENESE Med in the treatment of dystonias associated with Parkinson's disease: a multicenter, randomized, double-blind, placebo-controlled trial.

2028
Pivotal Study
2029

CE Class IIa Certification

French market launch

2029
CE Class IIa Certification
2030

Commercial expansion

EU market

2030
Commercial expansion
2031

FDA Approval

FDA 510(k) / De Novo
US market launch

2031
FDA Approval

AF GENESE Med